{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:19Z","timestamp":1786985419029,"version":"build-2736575974"},"reference-count":222,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["bloodreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.blre.2013.07.003","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T17:47:07Z","timestamp":1374947227000},"page":"243-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Current therapy of myelodysplastic syndromes"],"prefix":"10.1016","volume":"27","author":[{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Linhares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2013.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nrc3321","article-title":"The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes","volume":"12","author":"Raza","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.6004\/jnccn.2011.0006","article-title":"Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010","volume":"9","author":"Sekeres","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2013.07.003_bb0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2012.04.014","article-title":"Epidemiology of myelodysplastic syndromes","volume":"125","author":"Ma","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11899-012-0134-1","article-title":"What's all the fuss about? Facts and figures about bone marrow failure and conditions","volume":"7","author":"Mukherjee","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"10.1016\/j.blre.2013.07.003_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jhm.2049","article-title":"Myelodysplastic syndromes: what do hospitalists need to know?","volume":"8","author":"Zeidan","year":"2013","journal-title":"J Hosp Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0035","doi-asserted-by":"crossref","DOI":"10.1586\/17474086.2013.840997","article-title":"Myelodysplastic syndromes: towards a risk-adaptive treatment approach","author":"Faltas","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/asheducation.V2012.1.49.3798189","article-title":"Myelodysplastic syndromes: who and when in the course of disease to transplant","author":"Mufti","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2013.07.003_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2013.07.003_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0055","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0060","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.amjmed.2012.08.013","article-title":"Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS)","volume":"126","author":"Zeidan","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0065","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0070","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0075","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0080","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0085","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0090","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0095","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0100","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.4049\/jimmunol.1200602","article-title":"Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome","volume":"189","author":"Mailloux","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2013.07.003_bb0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/10428194.2012.718341","article-title":"Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group","volume":"54","author":"van de Loosdrecht","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb0110","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-012-1581-4","article-title":"Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine","volume":"92","author":"Breccia","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"issue":"suppl; abstr 7126","key":"10.1016\/j.blre.2013.07.003_bb0125","article-title":"Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza)","author":"Zeidan","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08893.x","volume":"155","author":"van der Helm","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0135","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2012.04.018","article-title":"Myelodysplastic syndromes: therapy and outlook","volume":"125","author":"Lyons","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0140","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2013-02-453068","article-title":"How we treat lower risk myelodysplastic syndromes","volume":"121","author":"Fenaux","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0145","doi-asserted-by":"crossref","DOI":"10.1586\/17474086.2013.814456","article-title":"Iron chelation therapy for myelodysplastic syndromes-associated iron overload: where do we stand?","author":"Mitchell","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1634\/theoncologist.2011-S3-35","article-title":"Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes","volume":"16","author":"Santini","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2013.07.003_bb0155","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2010.09.003","article-title":"Controversies surrounding iron chelation therapy for MDS","volume":"25","author":"Leitch","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2013.07.003_bb0165","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0170","first-page":"160","article-title":"A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes","volume":"1","author":"Oliva","year":"2011","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0175","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1365-2141.1998.01114.x","article-title":"\u2018Low-risk\u2019 myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins","volume":"103","author":"Parker","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0180","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1365-2141.1998.00708.x","article-title":"Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes","volume":"101","author":"Parker","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0185","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-013-1686-4","article-title":"High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM","volume":"92","author":"Kelaidi","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.seminhematol.2012.09.003","article-title":"Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins","volume":"49","author":"Santini","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","article-title":"NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes","volume":"9","author":"Greenberg","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2013.07.003_bb0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.1989.tb00215.x","article-title":"Circulating erythropoietin in patients with myelodysplastic syndromes","volume":"73","author":"Jacobs","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0210","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0215","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.leukres.2013.02.021","article-title":"Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines","volume":"37","author":"Davidoff","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0220","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0225","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.2007.06546.x","article-title":"Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes","volume":"137","author":"Golshayan","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0230","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2008.07181.x","article-title":"Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes","volume":"142","author":"Gabrilove","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0240","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstrom-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2011.049130","article-title":"Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes","volume":"97","author":"Davidoff","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0250","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","article-title":"Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy","volume":"87","author":"Negrin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3324\/haematol.2011.051755","article-title":"Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes","volume":"97","author":"Smith","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0260","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","article-title":"Distinct haematological disorder with deletion of long arm of no. 5 chromosome","volume":"251","author":"Van den Berghe","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.blre.2013.07.003_bb0265","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0270","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.leukres.2012.08.007","article-title":"Historical perspectives on myelodysplastic syndromes","volume":"36","author":"Steensma","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0275","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1002\/cncr.24575","article-title":"The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0280","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1586\/ehm.11.2","article-title":"Biology and treatment of the 5q\u2212 syndrome","volume":"4","author":"Padron","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0285","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q\u2212 syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.blre.2013.07.003_bb0290","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/EdBook_AM.2013.33.e256","article-title":"Myelodysplastic syndromes","author":"Bejar","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.blre.2013.07.003_bb0295","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/blood-2010-07-295238","article-title":"Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells","volume":"117","author":"Dutt","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0300","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/179402","article-title":"Important genes in the pathogenesis of 5q\u2212 syndrome and their connection with ribosomal stress and the innate immune system pathway","author":"Fuchs","year":"2012","journal-title":"Leuk Res Treat"},{"key":"10.1016\/j.blre.2013.07.003_bb0305","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/era.10.135","article-title":"Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes","volume":"10","author":"Heise","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.blre.2013.07.003_bb0310","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2010-12-324715","article-title":"Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q\u2212 syndrome","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0315","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.2174\/1381612811209023198","article-title":"Lenalidomide for treatment of myelodysplastic syndromes","volume":"18","author":"Komrokji","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.blre.2013.07.003_bb0320","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/leu.2011.391","article-title":"Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study","volume":"26","author":"Germing","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0325","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"Jadersten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0330","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/gcc.21993","article-title":"Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion","volume":"51","author":"Sebaa","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0335","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0340","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0345","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0350","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/blood-2011-07-369009","article-title":"Lenalidomide in MDS: 4th time's a charm","volume":"118","author":"Sekeres","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0355","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3324\/haematol.2011.045914","article-title":"Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies","volume":"97","author":"Ades","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0360","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/leu.2012.369","article-title":"Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis","volume":"27","author":"Kuendgen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0990","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00277-009-0846-z","article-title":"Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression","volume":"89","author":"Gohring","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0995","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2011.08979.x","article-title":"Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents","volume":"156","author":"Sibon","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb1000","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2007.15.5770","article-title":"Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes","volume":"26","author":"Sekeres","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb1005","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1371\/journal.pmed.0050035","article-title":"An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome","volume":"5","author":"Ebert","year":"2008","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.blre.2013.07.003_bb1010","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/leu.2013.59","article-title":"A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low\/int-1 risk MDS without del(5q)","volume":"27","author":"Sardnal","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb1015","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2008-08-175778","article-title":"Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study","volume":"113","author":"Ades","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb1020","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/asheducation-2011.1.556","article-title":"Immunomodulating drugs in myelodysplastic syndromes","author":"Ades","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2013.07.003_bb1025","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3324\/haematol.2010.039669","article-title":"Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities","volume":"96","author":"Mollgard","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb1030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11864-011-0165-1","article-title":"The 5q\u2212 syndrome: biology and treatment","volume":"12","author":"Padron","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb1035","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2013.07.003_bb1040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0609.2010.01473.x","article-title":"Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion","volume":"85","author":"Oliva","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb1045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2010.02.013","article-title":"Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions","volume":"24","author":"Komrokji","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2013.07.003_bb1050","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/onc.2012.139","article-title":"Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"Wei","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2013.07.003_bb1055","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/10428194.2012.710904","article-title":"Tertiary center referral patterns for myelodysplastic syndrome patients are indicative of age and race disparities: a single-institution experience","volume":"54","author":"Zandberg","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb1060","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ejh.12105","article-title":"Low RPS14 expression in MDS without 5q\u2014aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q\u2212 patients","volume":"90","author":"Wu","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb1065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2011-02-337303","article-title":"A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605","volume":"118","author":"Sekeres","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb1070","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/10428194.2011.623255","article-title":"A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q\u2014myelodysplastic syndromes","volume":"53","author":"Voutsadakis","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb1075","first-page":"920","article-title":"Targeted repression of TP53 promotes erythropoiesis in Del(5q) MDS and overcomes clinical resistance to lenalidomide","volume":"120","author":"Caceres","year":"2012","journal-title":"ASH Ann Meet Abstr"},{"key":"10.1016\/j.blre.2013.07.003_bb1080","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.leukres.2012.08.010","article-title":"New therapeutics for myelodysplastic syndromes","volume":"36","author":"List","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.07.003_bb1085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/BOR.0b013e32834db4ee","article-title":"Myelodysplasia and autoimmunity","volume":"24","author":"Giannouli","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.blre.2013.07.003_bb1090","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.exphem.2009.04.009","article-title":"Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset","volume":"37","author":"Fozza","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb1095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb1100","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb1105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000339498","article-title":"Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory T cells","volume":"128","author":"Fozza","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb1110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3324\/haematol.2009.006080","article-title":"Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance","volume":"94","author":"Barrett","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0365","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.seminhematol.2012.07.004","article-title":"Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab","volume":"49","author":"Parikh","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0370","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2010-04-277921","article-title":"T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy","volume":"117","author":"Sloand","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0375","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2004-05-2017","article-title":"Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome","volume":"106","author":"Sloand","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0380","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00277-005-1016-6","article-title":"Cyclosporin A in myelodysplastic syndrome: a preliminary report","volume":"84","author":"Dixit","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0385","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1532\/IJH97.A10513","article-title":"Treatment of myelodysplastic syndrome with cyclosporin A","volume":"85","author":"Chen","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0390","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","article-title":"Antithymocyte globulin for patients with myelodysplastic syndrome","volume":"99","author":"Molldrem","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0395","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","article-title":"A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia","volume":"120","author":"Killick","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0400","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care\u2014SAKK 33\/9","volume":"29","author":"Passweg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0405","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/sj.leu.2403124","article-title":"Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes","volume":"17","author":"Yazji","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0410","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","article-title":"A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes","volume":"18","author":"Stadler","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0415","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1200\/JCO.2010.29.7010","article-title":"Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions","volume":"28","author":"Sloand","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0420","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2010.08145.x","article-title":"Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study","volume":"149","author":"Scott","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0425","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2005.05360.x","article-title":"Activity of sirolimus in patients with myelodysplastic syndrome\u2014results of a pilot study","volume":"128","author":"Platzbecker","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0430","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.V100.5.1570.h81702001570_1570_1574","article-title":"HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome","volume":"100","author":"Saunthararajah","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0435","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0440","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","article-title":"Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy","volume":"26","author":"Sloand","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0445","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1517\/13543784.2011.559164","article-title":"Epigenetic regulation in myelodysplastic syndromes: implications for therapy","volume":"20","author":"Vigna","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.blre.2013.07.003_bb0450","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","article-title":"RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia","volume":"119","author":"Aimiuwu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0455","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428190801947575","article-title":"DNA methyltransferase inhibitors: class effect or unique agents?","volume":"49","author":"Griffiths","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb0460","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0465","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0470","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0475","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0480","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/asheducation-2011.1.550","article-title":"New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome","author":"Gore","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2013.07.003_bb0485","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0490","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2010.08082.x","article-title":"Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C","volume":"149","author":"Fenaux","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0495","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.hoc.2010.02.012","article-title":"Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes","volume":"24","author":"Steensma","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2013.07.003_bb0500","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.leukres.2010.05.021","article-title":"Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion","volume":"34","author":"Fenaux","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0505","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0510","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1002\/cncr.25774","article-title":"Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes","volume":"117","author":"Silverman","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.blre.2013.07.003_bb0515","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0520","series-title":"Myelodysplastic syndromes","article-title":"Management of high-risk myelodysplastic syndrome","author":"Zeidan","year":"2013"},{"key":"10.1016\/j.blre.2013.07.003_bb0525","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0530","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0535","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0540","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3109\/10428194.2011.643408","article-title":"Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response","volume":"53","author":"Breccia","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb0545","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1182\/blood-2012-04-422204","article-title":"Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort","volume":"119","author":"Itzykson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.173","article-title":"Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia","author":"Estey","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0555","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0560","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5days every 4weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0565","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","article-title":"DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes","volume":"28","author":"Shen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0570","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2010.01456.x","article-title":"Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine","volume":"85","author":"Santini","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0575","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0580","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0585","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2013.07.003_bb0590","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1365-2141.2012.09076.x","article-title":"Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure","volume":"157","author":"Prebet","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0595","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0600","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2011.04.011","article-title":"Failure of hypomethylating agent-based therapy in myelodysplastic syndromes","volume":"38","author":"Kadia","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0605","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0610","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.leu.2402591","article-title":"Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors","volume":"16","author":"Oosterveld","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0615","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.1997.2973114.x","article-title":"Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders","volume":"98","author":"Wattel","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0620","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","article-title":"High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens","volume":"92","author":"Beran","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0625","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ajh.22047","article-title":"Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Garcia-Manero","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0630","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/cncr.21699","article-title":"Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0635","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.22779","article-title":"Intensive chemotherapy is not recommended for patients aged >60years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes","volume":"110","author":"Knipp","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0640","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/cncr.25598","article-title":"Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome","volume":"117","author":"Bello","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0645","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.seminhematol.2012.07.003","article-title":"Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes","volume":"49","author":"Platzbecker","year":"2012","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1016\/j.blre.2013.07.003_bb0650","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1586\/ehm.13.30","article-title":"Higher-risk myelodysplastic syndromes with del5q: Is sequential azacitidine\u2013lenalidomide combination the way to go?","volume":"6","author":"Zeidan","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0655","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.seminhematol.2007.11.007","article-title":"DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes","volume":"45","author":"Griffiths","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0660","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2013.07.003_bb0665","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/13543784.2011.542750","article-title":"Vorinostat in acute myeloid leukemia and myelodysplastic syndromes","volume":"20","author":"Prebet","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.blre.2013.07.003_bb0670","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-011-1240-1","article-title":"Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)","volume":"91","author":"Cashen","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0675","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ajh.22198","article-title":"Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome","volume":"87","author":"Dimicoli","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0680","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2013.07.003_bb0685","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","article-title":"Antileukemia activity of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid","volume":"29","author":"Yang","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0690","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0695","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0700","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","article-title":"Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms","volume":"66","author":"Gore","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0705","first-page":"601","article-title":"Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905","volume":"116","author":"Prebet","year":"2010","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.blre.2013.07.003_bb0710","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"28","author":"Sekeres","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0715","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/blood-2012-06-434639","article-title":"Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes","volume":"120","author":"Sekeres","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2013.07.003_bb0720","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/leu.2013.26","article-title":"Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study","volume":"27","author":"Platzbecker","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0725","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/10428190903318329","article-title":"Report of a phase 1\/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes","volume":"51","author":"Borthakur","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb0730","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3109\/10428194.2010.551570","article-title":"Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed\/refractory acute myeloid leukemia","volume":"52","author":"Bayraktar","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb0735","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1080\/10428190802451254","article-title":"Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial","volume":"49","author":"Nand","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb0740","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2012-03-415661","article-title":"Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome","volume":"120","author":"Komrokji","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0745","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0750","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2010.32.1919","volume":"29","author":"Giralt","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0755","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.2174\/1381612811209023215","article-title":"Current status of allogeneic hematopoietic cell transplantation for MDS","volume":"18","author":"Xu","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.blre.2013.07.003_bb0760","first-page":"200","article-title":"Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions","volume":"4","author":"Giralt","year":"2005","journal-title":"Curr Hematol Rep"},{"issue":"21","key":"10.1016\/j.blre.2013.07.003_bb0765","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0770","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bbmt.2012.05.003","article-title":"Allogeneic hematopoietic cell transplantation in patients age 60\u201370years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine","volume":"18","author":"Platzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2013.07.003_bb0775","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0780","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.beha.2011.09.010","article-title":"The role of hematopoietic cell transplantation as therapy for myelodysplasia","volume":"24","author":"Appelbaum","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0785","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/asheducation-2010.1.325","article-title":"Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome","author":"Cutler","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2013.07.003_bb0790","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.hoc.2010.02.006","article-title":"Patient selection for transplantation in the myelodysplastic syndromes","volume":"24","author":"Cutler","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2013.07.003_bb0795","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.blre.2012.08.002","article-title":"Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?","volume":"26","author":"Gyurkocza","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2013.07.003_bb0800","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbmt.2010.09.006","article-title":"Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation","volume":"17","author":"Armand","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2013.07.003_bb0805","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.bbmt.2012.06.009","article-title":"Transplantation for MDS in the elderly: more evidence, or more bias?","volume":"18","author":"Cutler","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2013.07.003_bb0810","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00005-011-0152-z","article-title":"Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status","volume":"60","author":"Deeg","year":"2012","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.blre.2013.07.003_bb0815","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2008.12.003","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review","volume":"15","author":"Oliansky","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2013.07.003_bb0820","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2012-04-423046","article-title":"Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS","volume":"120","author":"Deeg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0825","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3324\/haematol.2010.033506","article-title":"Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome","volume":"96","author":"Della Porta","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0830","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0835","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2008.002063","article-title":"The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome","volume":"94","author":"Zipperer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0840","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3324\/haematol.2009.011429","article-title":"Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study","volume":"95","author":"Alessandrino","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2013.07.003_bb0845","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0850","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","article-title":"WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"112","author":"Alessandrino","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0855","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/bmt.2009.190","article-title":"Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity","volume":"45","author":"Lee","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2013.07.003_bb0860","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2009.26.3509","article-title":"Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome","volume":"28","author":"Faderl","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0865","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/cncr.26327","article-title":"A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome","volume":"118","author":"Faderl","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0870","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1021\/jm200570p","article-title":"Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2\u2032,4\u2032,6\u2032-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity","volume":"54","author":"Reddy","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2013.07.003_bb0875","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","article-title":"Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0880","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0885","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MOH.0b013e3283257a74","article-title":"Optimal sequencing of treatments for patients with myelodysplastic syndromes","volume":"16","author":"Itzykson","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2013.07.003_bb0890","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/cncr.25575","article-title":"A phase 1\u20132 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0895","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","article-title":"Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes","volume":"24","author":"Schiller","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0900","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2005.03.9503","article-title":"Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study","volume":"24","author":"Vey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0905","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.leukres.2012.11.001","article-title":"Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy","volume":"37","author":"Duong","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0910","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1182\/blood-2009-01-176032","article-title":"Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome","volume":"113","author":"Raza","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0915","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-5-18","article-title":"Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)","volume":"5","author":"Raza","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0920","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.25545","article-title":"Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2013.07.003_bb0925","first-page":"923","article-title":"Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS)","volume":"120","author":"Oliva","year":"2012","journal-title":"ASH Ann Meet Abstr"},{"key":"10.1016\/j.blre.2013.07.003_bb0930","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2013.07.003_bb0935","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14728222.9.4.831","article-title":"Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors","volume":"9","author":"Muller","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.blre.2013.07.003_bb0940","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","article-title":"Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?","volume":"118","author":"Ustun","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0945","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/0008-5472.CAN-10-2933","article-title":"Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase","volume":"71","author":"Zhou","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2013.07.003_bb0950","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0955","first-page":"586","article-title":"Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss","volume":"12","author":"Raje","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.blre.2013.07.003_bb0960","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2009.27.6295","article-title":"Phase I\/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia","volume":"28","author":"Lowenberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2013.07.003_bb0965","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/10428190802322919","article-title":"Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment","volume":"49","author":"Navas","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2013.07.003_bb0970","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2006-05-023093","article-title":"Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors","volume":"108","author":"Navas","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2013.07.003_bb0975","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/leu.2012.264","article-title":"Randomized, dose-escalation study of the p38alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome","volume":"27","author":"Sokol","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2013.07.003_bb0980","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1172\/JCI31809","article-title":"New molecularly targeted therapies for lung cancer","volume":"117","author":"Sun","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2013.07.003_bb0985","first-page":"424","article-title":"Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies","volume":"118","author":"Jamieson","year":"2011","journal-title":"ASH Ann Meet Abstr"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X13000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X13000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T10:24:34Z","timestamp":1715768674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X13000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":222,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0268960X13000386"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2013.07.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current therapy of myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2013.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}